Celebrex Generic Exclusivity Suit Could Have Broad Financial, Regulatory Reach
Executive Summary
Appeals court says FDA violated Hatch-Waxman by awarding 180-day exclusivity solely to Teva based on reissued patent; celecoxib generics are already marketed but could step out from Pfizer-authorized status.
You may also be interested in...
Patent Regulation Drops Deference To ANDA, 505(b)(2) Sponsors
FDA's final rule implementing provisions of Medicare Modernization Act ‘will fuel litigation,’ attorney predicts.
Par Fights FDA Forfeiture Of Generic Colcrys Exclusivity
Pursing legal action against the agency in an area where it is sometimes vulnerable, Par argues that amending its proposed label did not interrupt paragraph IV certification for the firm's colchicine ANDA.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.